INDIANAPOLIS, July 27 /PRNewswire-FirstCall/ -- Eli Lilly and Company continues to lead the way in advancing lung cancer treatment. On the heels of new FDA and European Commission approvals for ALIMTA(®) (pemetrexed for injection) as a treatment for nonsquamous non-small cell lung cancer (NSCLC) in the maintenance setting, the company will release findings from more than 30 lung cancer studies at the 13th World Conference on Lung Cancer (WCLC) in San Francisco, Calif., from July 31 to Aug. 4, 2009. WCLC is sponsored by the International Association for the Study of Lung Cancer. Data will feature Lilly's ALIMTA and GEMZAR(®) (gemcitabine HCl for injection).
